Skip to content
Calculator
Guide

How peptide drugs are made: from amino acids to a sterile pen, and what '99%' leaves out

Last updated: November 4, 2026 · 19 min read · By the Grey Peptides Editorial Board

Chemists in protective gear performing an experiment in a laboratory
Photo by Mikhail Nilov on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • Most peptide drugs are built one amino acid at a time on tiny resin beads, a method invented in 1963. Longer ones, such as insulin, are made by engineered microbes instead.
  • Purifying the crude peptide by preparative chromatography is the hardest step: it accounts for about half of the material a synthetic peptide process uses.
  • Making a kilogram of peptide by solid-phase synthesis used an average of about 13,000 kilograms of solvents, reagents and water in an industry survey, far more than for small-molecule drugs.
  • After purification, the peptide is freeze-dried and filled into vials, cartridges or pens under sterile conditions, then tested for sterility and endotoxin batch by batch.
  • An HPLC purity of 99% describes the main peak on a chromatogram. It does not tell you the salt form, how much of the powder is peptide, or whether the vial is sterile.

The building blocks: 20 amino acids, and the ones chemists add

A peptide is a short chain of amino acids joined end to end. Living cells build their proteins from twenty amino acids, called the proteinogenic or canonical amino acids 1. Many peptide drugs use more than those twenty. Chemists add non-canonical amino acids to make a peptide more stable in the body, more selective for its target or more potent (review) 1.

Two approved drugs show what that looks like on a label. Tirzepatide contains aminoisobutyric acid (Aib), which is not one of the twenty, at positions 2 and 13, and a fatty acid attached through a linker to the lysine at position 20 2. Octreotide, an eight-amino-acid drug that mimics the hormone somatostatin, contains D-phenylalanine and D-tryptophan, the mirror-image forms of two amino acids, and two of its cysteines are joined by a sulfur bridge that closes it into a ring 3. So a D form can be a deliberate design choice in one peptide and an impurity in another: a 2024 review counts racemisation, the flipping of an amino acid into its mirror form, among the most common side reactions in peptide synthesis (review) 4.

Whether a molecule counts as a peptide or a protein in US law depends on its length, a line our article on what makes a peptide a peptide explains. Chemical synthesis is filed as a new drug application when the chain is 40 amino acids or fewer, while recombinant peptides are filed as biologics 5.

Protecting groups and resins: why the chemistry needs a handle and a mask

An amino acid has two reactive ends, an amine and an acid, and many have a reactive side chain as well. If you simply mixed amino acids together, they would join in random order. So chemists cover, or protect, every reactive group they do not want to react, and uncover one at a time. Whole reviews catalogue the protecting groups used for each kind of side chain (review) 6. Two families of temporary protecting groups for the chain's growing end, Boc and Fmoc, made modern synthesis practical (review) 7. In the common Fmoc method, the side chains carry acid-sensitive groups such as tert-butyl (tBu), which stay on until the very end 5.

The handle is the resin: a bead of polymer to which the first amino acid is attached. Because the growing chain stays fixed to the bead, every leftover reagent can be washed away after each step, and the chain is cut from the bead only when it is complete. That final cut is usually made with trifluoroacetic acid (TFA), mixed with scavengers that stop the released protecting-group fragments from reattaching to the peptide 5 8.

Solid-phase synthesis: one amino acid per cycle

Solid-phase peptide synthesis was invented by Bruce Merrifield in 1963 7, and it is now the main platform for making synthetic peptides 5. The chain is built from its tail end forward, one amino acid per cycle. In each cycle the protecting group on the chain's free end is removed (in Fmoc chemistry, with the base piperidine), the resin is washed, the next protected amino acid is added with a coupling reagent that joins it to the chain, and the resin is washed again 5. A 20-amino-acid peptide needs about 20 such cycles before the final cut from the resin.

Each step is pushed to completion with a large excess of protected amino acid, coupling additive and base, and the resin is rinsed with a large excess of solvent after every coupling and every deprotection 5. Even so, no step is perfect. A 2013 review notes that in the original method the purity of the final product fell as the number of coupling steps rose, a problem later reduced by better protecting groups and techniques (review) 7. A chain that missed one amino acid in one cycle, or picked up an extra one, is almost the same molecule as the one intended, which is what makes it hard to remove later.

Solution-phase, fragment and hybrid routes

Peptides can also be built in solution, without a resin. The Roundtable's 2024 review says this liquid-phase approach offers advantages for shorter peptides of around 5 to 10 amino acids: each step can be optimised and monitored, less reagent can be used, and impurities can be removed between steps. The costs are a longer, more expensive development and less automation (review) 5.

For longer chains, the two can be combined. In a fragment or hybrid route, short pieces are made by solid-phase synthesis and then joined together in solution. The review names enfuvirtide, an HIV drug, as an early example of production at scale by this approach, and tirzepatide as a recent one 5. A 2003 account by a chemist at enfuvirtide's developer describes how the 36-amino-acid drug was scaled up to commercial production by chemical synthesis 9. Fragment joining was popular in the 1980s but suffered from racemisation and difficult reactions, and newer ligation chemistries for joining unprotected pieces have since been developed (review) 7.

Recombinant expression: letting a cell build the chain

The other way to make a long chain is to have a microbe make it. Insulin human, the hormone in Humulin R, is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli, according to its label 10. Somatropin, the 191-amino-acid growth hormone in Genotropin, is also made in E. coli 11.

Some drugs are made partly in cells and partly by chemistry. Saxenda's label says liraglutide's peptide precursor is produced by a process that includes expressing recombinant DNA in the yeast Saccharomyces cerevisiae, and the drug is then made by attaching a fatty acid with a glutamic acid spacer to the lysine at position 26 12. Wegovy's label says semaglutide's peptide backbone is produced by yeast fermentation 13.

Recombinant production is used mainly for long sequences made only of natural L-amino acids. When it fits, it can bring the cost down many times over, according to the Roundtable review 5. The route also leaves its own fingerprint: a 2020 study by Novo Nordisk scientists found that synthetic and recombinant liraglutide from five suppliers each had an impurity profile distinct from the originator's (laboratory study) 14. FDA's 2021 guidance covers synthetic generic versions of five peptides whose reference products are of recombinant origin (glucagon, liraglutide, nesiritide, teriparatide and teduglutide), and asks for every new impurity of up to 0.5% to be characterised and justified 15. Two products with the same name and the same main molecule are not necessarily the same product.

Where impurities come from

Because synthesis happens step by step, the most common impurities are near-copies of the intended peptide. A 2025 paper lists impurities arising from insertion, truncation, deamidation, isomerisation, oxidation and the manufacturing process itself (commentary by an author at a contract peptide manufacturer) 16. In plain terms: a chain missing an amino acid (a deletion or truncation), a chain with an extra one (an insertion), or a chain where an amino acid has been chemically altered, for example by oxidation or loss of an amide group. Regulators call these peptide-related impurities, or related substances 15.

A subtler problem is chirality. Racemisation during synthesis, or impure starting materials, can introduce the mirror-image (D) form of an amino acid the drug is meant to carry in its L form, which can change how a peptide works (review) 4. These mirror-image impurities have the same mass as the intended peptide, so a simple mass check will not spot them.

Impurities matter for more than potency. A 2023 review, by a company that sells immunogenicity screening, explains that peptide drug impurities can introduce new sequences the immune system may react to, which is why FDA's generic pathway asks for information on any new impurity compared with the original product (review) 17. The 2020 Novo Nordisk study also found that trace metals increased the formation of large aggregates of liraglutide (laboratory study) 14.

Purification: the bottleneck

What comes off the resin is crude peptide: the intended chain mixed with its near-copies, cleaved protecting groups and leftover reagents. Separating the right molecule from molecules that differ by one amino acid is the job of preparative chromatography, which the Roundtable review calls the established technology for purifying most peptide drugs because it is the most efficient way to separate substances with similar structures. Most processes combine two or three chromatography steps, usually reversed-phase and ion-exchange, each separating by a different property 5.

That step is where much of the cost in materials lies. The review reports that purification and the steps after it account directly for about half of a synthetic peptide process's material use, because the product is handled in dilute solution and run through long chromatography gradients. It adds a second cost: every gram lost during purification has to be made up by making more crude peptide in the first place 5. In one process described in detail, a Bristol Myers Squibb team that made 800 g of a macrocyclic peptide reported that the final preparative chromatography drove a large share of the process's waste 18.

Chromatography also decides the salt the peptide ends up as. Trifluoroacetic acid is used as an ion-pairing reagent in the purifying columns as well as to cut peptides from the resin, so a synthetic peptide usually comes out as a TFA salt unless the counter-ion is exchanged, for example for chloride (laboratory study) 8. Approved drugs state their salt form: Sandostatin's label describes octreotide as the acetate salt and gives each ampul's content 'as acetate' 3.

Freeze-drying: turning a dilute solution into a stable powder

The purified peptide is collected as a dilute solution in water and organic solvent. The review says the usual way to recover it as a dry powder is lyophilisation, or freeze-drying: the organic solvent is removed, the solution passes through a final microfiltration to reduce its microbial load, and it is freeze-dried. Large tray freeze-dryers are used for batches of under 50 kg, and freeze-drying was the near-universal final isolation step in the processes the Roundtable surveyed. It uses a lot of energy, but little material, and recovers the peptide with high yield 5.

Freeze-drying matters again in the finished medicine. Peptides and proteins have limited chemical and physical stability in water, and drying them, most often by freeze-drying, is how many are kept stable for storage and shipping, at a cost in time and energy (review) 19. Genotropin, for example, is a sterile, white freeze-dried powder in a two-chamber cartridge, with the drug in the front chamber and the liquid used to dissolve it in the rear chamber 11.

Sterile fill-finish: vials, cartridges and pens

A powder in a drum is not yet a medicine. The last stage, called fill-finish, puts the drug into the container a patient uses, and for an injected drug it has to be sterile. FDA's guidance on sterile drugs says aseptic processing should be used only when sterilising the product in its final container (terminal sterilisation) is not feasible. In aseptic processing the drug, the container and the closure are each sterilised separately and brought together in a critical area whose air meets ISO 5 (Class 100), and air samples there should normally contain no microorganisms 20. Because there is no step that sterilises the product once it is sealed, the filling environment carries the whole burden 20.

The container is part of the product. Humulin R comes in 10 mL and 3 mL multiple-dose vials 10; Sandostatin in 1 mL ampuls 3; Genotropin in a two-chamber cartridge for a reusable pen 11; Saxenda in a prefilled pen holding 3 mL 12; Wegovy in single-dose pens and syringes and a single-patient-use FlexTouch pen 13; and Mounjaro in single-dose pens and vials, multi-dose vials and a four-dose KwikPen 2. Multi-dose containers add a preservative, such as metacresol in Humulin R or phenol in Saxenda 10 12.

Then each batch is tested. Federal manufacturing rules require appropriate laboratory testing of each batch of a drug product sold as sterile or pyrogen-free 21. FDA's endotoxin guidance, in its second edition of March 2026, recommends testing components and finished products for bacterial endotoxins, and notes FDA has accepted the Limulus amebocyte lysate (LAL) test in place of the older rabbit pyrogen test for more than 30 years 22.

The waste problem: thousands of kilograms per kilogram

Peptide chemistry is wasteful, and the industry has measured how wasteful. In 2016 the American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable, a group of pharmaceutical companies, named greener processes for peptide drugs a critical unmet need. Its 2019 perspective in the Journal of Organic Chemistry, by chemists at eight drug companies, said the state of the art relied mainly on legacy technologies using large amounts of highly hazardous reagents and solvents 23.

The measure the Roundtable uses is process mass intensity (PMI): the total mass of everything put into a process (solvents, reagents, water) for each kilogram of drug that comes out. In its 2024 survey, fourteen member companies reported PMI for 40 synthetic peptide processes 5:

How the drug is madeKilograms of material used per kilogram of drug (PMI)What was measured
Small-molecule drugs168 to 308 (median range)Figures the Roundtable paper cites for comparison
Biologics such as antibodiesAbout 8,300 (average)Figure the Roundtable paper cites for comparison
Peptides by solid-phase synthesis, phase 3 and commercial1,684 to 34,585 (average 13,063)14 processes, peptides of 6 to 43 amino acids (average 19)
Peptides by solution-phase synthesis1,139 to 9,019 (average 3,984)4 processes from phase 1 to commercial, peptides of 10 to 20 amino acids

The solution-phase figures come from only four shorter peptides, so they show a direction rather than a settled difference 5. The largest single organic solvent in solid-phase synthesis was DMF, at 39%, used for the washes between every step; acetonitrile, used in chromatography, was about 10%. DMF and its close relatives NMP and DMAc are classified as toxic to reproduction, and their use may be restricted 5. None of this affects the safety of an approved drug in the vial. It is a measure of how many steps, and how much material, making a peptide properly takes.

Impurities after manufacture: storage and stress

Purity is not fixed at the factory. Peptides can break down after they are made, especially with heat and light. In a 2025 study, researchers exposed synthetic liraglutide to heat and light stress and identified ten impurities, including four degradation products not reported before, and mapped where on the chain the changes occurred (laboratory study) 24. The study's authors note that peptides are prone to degradation under improper storage or handling 24. So a certificate issued when a batch was made may say little about a vial that has since been exposed to heat or light. Our travel guide lists the labelled storage limits for approved pens.

What '99% purity' actually measures

The purity figure on most certificates comes from high-performance liquid chromatography (HPLC) with a UV detector: the sample is separated into peaks, and purity is the main peak's share of the total peak area. That number is useful, but it is narrower than it sounds. Impurities do not all absorb UV light equally, so their peaks can over- or under-state how much is really there unless relative response factors are measured 16. Impurities that elute with the main peak can hide inside it.

More importantly, HPLC purity says nothing about what else is in the powder. A peptide powder also contains water, counter-ions and sometimes fillers. When Chinese metrologists assigned the true purity of a synthetic glucagon by measuring and subtracting every component, including water, TFA, inorganic ions and peptide impurities, they found 896 mg of glucagon per gram of sample, about 90% (mass-balance study) 25. A vial whose label says 10 mg of peptide, filled by weighing 10 mg of powder, would contain less than 10 mg of the peptide itself.

What a certificate saysWhat it measuresWhat it can miss
HPLC purity, e.g. 99%The share of UV-absorbing peptide material under the main peakWater, salts (such as TFA), fillers, and impurities that absorb UV differently or hide under the main peak
Mass spectrometry identityThat a molecule of the right mass is presentHow much is present; mirror-image (D-amino acid) versions with the same mass
Net peptide contentHow much of the powder's weight is actually peptideA separate measurement; an HPLC purity figure does not give it
Sterility and endotoxinMicrobes and bacterial toxinsSeparate tests; neither HPLC purity nor mass spectrometry detects them

Salt forms: the TFA question

Because trifluoroacetic acid is used both to cut peptides from the resin and in purification, synthetic peptides usually come out as TFA salts. A 2025 study notes that numerous studies highlight negative effects of TFA salts in biological assays, and showed TFA could be exchanged for chloride (laboratory study) 8. A research certificate rarely says which salt form is present or how much of the powder's weight it accounts for, which is one more reason a milligram of powder is not a milligram of peptide 25. Our article on endotoxin, heavy metals and TFA covers what is known about each in injected products.

What purity tests can miss entirely

Some contaminants are invisible to standard UV-based HPLC. In 2019, researchers using NMR found that two custom synthetic peptides bought commercially contained 20% and 43% mannitol by weight, an undeclared sugar alcohol that does not absorb UV light and so did not show up in routine chromatography (analytical study) 26. A 'pure' peptide by HPLC can be substantially something else by weight.

Falsified products are worse. A Belgian study of the ten falsified peptide drugs most often found on that market, bought from suspected illegal internet pharmacies, found large variation in drug per unit, purities ranging from 5% to 75% for cysteine-containing peptides, and the toxic elements arsenic, in several samples at up to ten times the international limit for injectable drugs, and lead, in one sample (market surveillance) 27. A 2024 study of semaglutide bought online without a prescription found vials holding 29% to 39% more semaglutide than labelled, one with endotoxin measured at 8.95 EU/mg (test purchase) 28.

How regulators set limits for approved peptides

Approved peptide drugs are held to specifications. FDA's 2021 guidance on generic synthetic versions of the five peptides first made recombinantly asks applicants to identify every peptide-related impurity at 0.10% or more, says a new one above 0.5% of the drug substance could raise immunogenicity concerns that the generic pathway may not be able to address, and asks for each new one up to 0.5% to be characterised and justified as not affecting safety or effectiveness 15. That is a far more detailed standard than a single purity percentage, and it sits on top of the aseptic filling and batch testing described above 21.

Research peptides sit outside that system. Our guide to 'research use only' explains what that label does and does not promise, and our article on retatrutide testing shows what buyer-submitted certificates can and cannot reveal.

A pharmacy product and a grey-market vial: what the process means for you

Every stage above leaves a trace that a buyer can ask about. An approved product's label and specification answer most of the questions; for an unregulated vial, each answer exists only if someone tested for it and reported the result.

QuestionApproved pharmacy productUnregulated vial
Related-substance impuritiesHeld to a specification; for FDA's synthetic generics, each one at 0.10% or more identifiedUnknown unless a test reports them; a single purity figure does not list them
Salt form (counter-ion)Stated on the label, e.g. octreotide 'as acetate'Rarely stated; a TFA salt adds weight that is not peptide
EndotoxinTested under FDA's endotoxin guidance and the batch-testing ruleOnly if someone ran a separate test
SterilityMade under FDA's sterile manufacturing rules and tested batch by batchOnly if someone ran a separate test; the certificate rarely says
Amount in the containerStated per vial, cartridge or pen dosePublished test purchases have found far more or far less than the label

The table rests on the sources cited above: the impurity thresholds on FDA's 2021 guidance 15, the salt form on the Sandostatin label 3, the testing on federal rules and FDA's endotoxin and aseptic guidance 21 22 20, and the amounts on the 2024 semaglutide test purchases and the Belgian screen 28 27.

Our COA Decoder walks through each line of a certificate. In short: identity by mass spectrometry shows the right molecule is present but not how much or whether its amino acids are the right mirror form; HPLC purity describes the main peak, not the powder; net peptide content, when reported, tells you how much of the weight is peptide; and sterility and endotoxin results, which matter most for anything injected, come only from separate tests that a certificate may or may not report. What independent laboratories have found when they tested products is collected in our published test results, and our guide to spotting a fake COA covers forgeries.

If you are holding a vial of powder that you mix yourself, the fill-finish step that an approved cartridge went through in ISO 5 air happens on your kitchen table instead. Our reconstitution guide covers the clean technique and the arithmetic, and it cannot add the sterility test the vial never had.

  • Was it made under good manufacturing practice, as an approved product, or labelled for research?
  • Does the certificate report net peptide content, salt form and water, or only HPLC purity?
  • Was it tested for sterility and endotoxin?
  • Is the certificate for this batch, and was the sample chosen by the seller?

The bottom line

A peptide drug is assembled one amino acid at a time on a resin, joined from fragments, or grown in a microbe; then it is separated from its near-copies by chromatography, freeze-dried, and filled into a sterile container that is tested batch by batch. The purification alone uses about half the material, and the whole synthetic process uses thousands of kilograms of material for each kilogram of drug. A 99% HPLC purity measures the main peak, not the salt, the water, the sterility or the endotoxin. A purity number is a starting point, not a verdict.

Frequently asked questions

How are peptide drugs made?

Most synthetic peptides are made by solid-phase peptide synthesis: protected amino acids are added one at a time to a chain anchored on a resin bead, then the chain is cut off, purified by chromatography and freeze-dried. Longer peptides such as insulin are made by engineered bacteria or yeast.

What is solid-phase peptide synthesis?

A method invented by Bruce Merrifield in 1963 in which the growing chain is attached to a resin bead. Each cycle removes a protecting group, adds the next amino acid and washes away the leftovers, so a 20-amino-acid peptide takes about 20 cycles.

Why are peptides expensive to make?

Each step uses a large excess of reagents and solvent, and separating the right chain from near-copies needs repeated preparative chromatography. An industry survey found an average of about 13,000 kg of material used per kg of peptide for commercial and late-stage solid-phase processes.

What does 99% purity mean for a peptide?

It usually means the main HPLC peak makes up 99% of the UV-detected peak area. It does not show how much of the powder is peptide, or whether water, salt, fillers or microbes are present.

What is a TFA salt?

Trifluoroacetic acid is used to cut peptides from the resin and to purify them, so synthetic peptides often end up as TFA salts. Studies report that TFA salts can affect biological assays, and the salt adds weight that is not peptide. Approved products state their salt form, such as octreotide acetate.

Are research peptides tested for sterility?

Only if the seller ran separate sterility and endotoxin tests; an HPLC purity or mass spectrometry result does not show either. Drugs sold as sterile must be tested batch by batch under federal manufacturing rules.

Sources

  1. Grob, N. M. (2025). Beyond the Canonical 20: Peptide Discovery with Non-Canonical Amino Acids. Chimia (Aarau), 79(11), 759-764. PMID: 41317068
  2. Eli Lilly. MOUNJARO (tirzepatide) US prescribing information, section 11 (Description). DailyMed version 40, effective August 27, 2026; read November 4, 2026. DailyMed
  3. Novartis. SANDOSTATIN (octreotide acetate) injection, US prescribing information, section 11 (Description). DailyMed version 23, effective July 22, 2026; read November 4, 2026. DailyMed
  4. Badgujar, D., et al. (2024). Enantiomeric purity of synthetic therapeutic peptides: A review. Chirality, 36(3). PMID: 38448043
  5. Kekessie, I., et al. (2024). Process Mass Intensity (PMI): A Holistic Analysis of Current Peptide Manufacturing Processes Informs Sustainability in Peptide Synthesis. J Org Chem, 89(7), 4261-4282. PMID: 38508870
  6. Isidro-Llobet, A., et al. (2009). Amino acid-protecting groups. Chem Rev, 109(6), 2455-504. PMID: 19364121
  7. Chandrudu, S., et al. (2013). Chemical methods for peptide and protein production. Molecules, 18(4), 4373-88. PMID: 23584057
  8. Erckes, V., et al. (2025). Towards a Consensus for the Analysis and Exchange of TFA as a Counterion in Synthetic Peptides and Its Influence on Membrane Permeation. Pharmaceuticals (Basel), 18(8). PMID: 40872554
  9. Bray, B. L. (2003). Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov, 2(7), 587-93. PMID: 12815383
  10. Eli Lilly. HUMULIN R (insulin human) injection, US prescribing information, sections 3 and 11. DailyMed version 35, effective June 16, 2026; read November 4, 2026. DailyMed
  11. Pfizer. GENOTROPIN (somatropin) US prescribing information, sections 3 and 11 (Description). DailyMed version 37, effective August 4, 2026; read November 4, 2026. DailyMed
  12. Novo Nordisk. SAXENDA (liraglutide) US prescribing information, section 11 (Description). DailyMed version 22, effective February 25, 2026; read November 4, 2026. DailyMed
  13. Novo Nordisk. WEGOVY (semaglutide) US prescribing information, sections 3 and 11 (Description). DailyMed version 19, effective June 18, 2026; read November 4, 2026. DailyMed
  14. Staby, A., et al. (2020). Influence of Production Process and Scale on Quality of Polypeptide Drugs: a Case Study on GLP-1 Analogs. Pharm Res, 37(7), 120. PMID: 32514880
  15. U.S. Food and Drug Administration. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin: Guidance for Industry. May 2021 (final; docket FDA-2017-D-5767). Text read October 27, 2026 in the National Library of Medicine's archived copy; FDA's guidance page re-read the same day. The older download link fda.gov/media/107622 is not used: it returned Page Not Found earlier on October 27, 2026 and later that day served the October 2017 draft instead. FDA guidance page
  16. Kumar Kuril, A. (2025). The Critical Need for Implementing RRF in the Accurate Assessment of Impurities in Peptide Therapeutics. Anal Chem, 97(24), 12480-12485. PMID: 40499007
  17. De Groot, A. S., et al. (2023). Immunogenicity risk assessment of synthetic peptide drugs and their impurities. Drug Discov Today, 28(10), 103714. PMID: 37467878
  18. Mukherjee, S., et al. (2024). Process Development of a Macrocyclic Peptide Inhibitor of PD-L1. J Org Chem, 89(10), 6651-6663. PMID: 38663026
  19. Mane, A. V., et al. (2026). Metamorphosis in Drying Techniques for Biopharmaceuticals. Int J Pharm Compd, 30(4), 345-357. PMID: 42752427
  20. U.S. Food and Drug Administration. Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice. Guidance for Industry, September 2004, sections II.B, III and IV.A. Read November 4, 2026. FDA guidance page
  21. 21 CFR 211.167(a), Special testing requirements (current good manufacturing practice for finished pharmaceuticals). eCFR text read October 27, 2026.
  22. U.S. Food and Drug Administration (CDER, CBER, CVM, CDRH, ORA). Pyrogen and Endotoxins Testing: Questions and Answers, Edition 2. Guidance for Industry, March 2026 (version 1 published 2012). Read November 4, 2026. FDA
  23. Isidro-Llobet, A., et al. (2019). Sustainability Challenges in Peptide Synthesis and Purification: From R&D to Production. J Org Chem, 84(8), 4615-4628. PMID: 30900880
  24. Badgujar, D., et al. (2025). Assessment of Thermal and Photolytic Stress Effects on the Stability of Primary Structure of Synthetic Liraglutide Using LC-HRMS/MS. J Pept Sci, 31(9), e70050. PMID: 40814845
  25. Wang, X., et al. (2020). Purity determination of synthetic glucagon using a mass balance approach. Sci Rep, 10(1), 4423. PMID: 32157163
  26. Choules, M. P., et al. (2020). NMR reveals an undeclared constituent in custom synthetic peptides. J Pharm Biomed Anal, 178, 112915. PMID: 31671336
  27. Janvier, S., et al. (2018). Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta, 188, 795-807. PMID: 30029448
  28. Ashraf, A. R., et al. (2024). Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. J Med Internet Res, 26, e65440. PMID: 39509151

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead